drugset
drugset / Trial / NCT04838639

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects

NCT04838639 ↗

Phase 1 Completed 84 enrolled Otsuka Pharmaceutical Factory, Inc. Celerion · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This clinical trial is the first-in-human study of NO-13065. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses and food effect of NO-13065 in healthy and obese adult subjects.

Timeline

Start
2021-06-14
Primary completion
2022-03-31
Completion
2022-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject NO-13065 Unknown — Oral

Indications

obesity disorder